Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only 2+% shorts. 60000 shares is easy to cover. Need more exposure
What you hearing ?
Trap the shorts. No shares left to borrow. Set sells high! Mines $30
With a 2.9M float if you set high limit sells it will force the shorts to buy higher to get out
Ra Medical Systems to Participate in the Piper Sandler Virtual Health Care Conference
$RMED - more insider buys!
They are buying hand over fist lately.
PT $28
2.9M share float.
$rmed $6.6 ^ 0.21 (3.29%)
Volume: 245,520 @11/23/20 4:10:00 PM EST
With strong volume a break of $8
I'm set real close to that also
SET SELLS HIGH TO TRAP SHORTS!
Mine is at $30.
No shares left to borrow.
Only 2.9M float.
SET EM HIGH ANF FORGET IT!
Board of directors just bought 4K shares each at $5.77
Ceo CFO and president just acquired 100s of thousands of shares.
Join us for a webcast discussing The Inimitable Role of Excimer Laser During the Pandemic, featuring Theodore J. Daly, MD, 33-year dermatology veteran with more than 20 years of experience using excimer lasers. December 2, 2020, 7-8 p.m. ET. Register: https://t.co/krtu2gKHdX pic.twitter.com/VwlRSpczvR
— Ra Medical Systems (@Ra_Medical) November 19, 2020
Maxim $1.50 PT pre split.
Now adjusted post split
I can't find that info. Can you provide a link?
Maxim group
Ra Medical Systems to Participate in A.G.P.’s Virtual Healthcare Symposium
Ra Medical reported cash and cash equivalents of $33.6 million as of September 30, 2020.
Still tons of cash. Everything ahead of schedule including the trial and catheter improvements.
Still 2.5X's cash on hand compared to MARKET CAP!
Quarterly loss cut in half.
Ra Medical Systems to Host Webcast Discussing the Role of Excimer Lasers in the Treatment of Psoriasis during the Pandemic
- call ended.
Vote approved.
Compliance will now be met.
Highly anticipating the Thursday earnings call.
$rmed $0.208 v -0.0079 (-3.66%)
Volume: 1,309,276 @11/10/20 4:10:00 PM EST
Ra Medical Systems Hosts Summit with Vascular Physicians to Monitor Progress on Next-Generation DABRA Catheter Design
Source: Business Wire
Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces a one-day DABRA Summit, during which participants will have the opportunity to provide input on the design features and enhancements for the Company’s next-generation DABRA catheters. Principal investigators and study coordinators from Ra Medical’s DABRA pivotal atherectomy clinical trial will also meet to share with one another insights on best practices.
“Convening this DABRA Summit with leaders in the field of vascular surgery, interventional radiology and interventional cardiology demonstrates our progress in engineering the next-generation DABRA catheter. This hands-on workshop will allow us to incorporate input on the usability and performance features we are building into our next-generation DABRA catheters,” said Will McGuire, Ra Medical Systems CEO. “We are highly focused on providing an enhanced product that exceeds their expectations.
“We also will be meeting with the clinical investigators for the atherectomy trial. With patient enrollment now open in five clinical sites, we will use this forum to share best practices in driving successful enrollment, patient outcomes and subject retention,” he added. “Making improvements and enhancements to our DABRA catheter along with advancing the atherectomy trial are our top priorities, and these meetings are expected to provide critical information to support our success.”
DABRA is Ra Medical’s excimer laser system used by physicians as a tool in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease, a form of peripheral artery disease.
RMED shareholders REJECTED Reverse Split.
Delisting by end of month
Yup
Cheers
Ra Medical Systems to Report Third Quarter 2020 Financial Results on November 12, 2020
It can't RS until they scam enough votes - next attempt is set for Nov 10th since the Nov 2nd didn't get enough idiots to support their plan.
You would think a company would spend a lil more time on business instead of artificially inflating the share price for an hour or 2.
I believe Nov 10 will be their 5th attempt at getting it......... Shareholders should have replaced all the directors, what a worthless bunch.
Watching PPS slowly decline, RS soon. Will A/S remsin the same?
RMED
This pos will be OTC PINK soon lol...
.01s
With the amount of cash they have they could buy back 20% of the companies shares, boost confidence and the share price, fix delisting issues, AND STILL HAVE $30M cash left over!!!
LET THEM KNOW YOU WANT A SHARE BUYBACK!!!
$rmed $0.1801 v -0.0176 (-8.90%)
Volume: 2,398,849 @10/30/20 7:57:10 PM EDT
PLEASE VOTE AGAINST THE REVERSE SPLIT
CHEERS!
If you haven't voted FOR the RS here is the number to call to vote.
833-945-2699
They need to approve the plan to meet their NYSE compliance plan.
Let's get this passed and move on.
$41M CASH!
$17M MARKET CAP!
2 approved FDA devices.
Another device trial running.
New CEO
Yeah with a Big RS lol
News : Ra Medical Systems Announces 10 Subjects Have Been Enrolled in its DABRA Pivotal Atherectomy Clinical Trial
$rmed $0.26 v -0.0079 (-2.95%)
Volume: 4,079,293 @10/02/20 7:53:08 PM EDT
Holdings
INTRACOASTAL CAPITAL - 4.6M
ARMISTICE CAPITAL - 3.8M
LYTTON LAURENCE - 3.7M
Renaissance Tech - 870K
Alethea Capital - 525K
Royce & Assoc. - 508K
Principal Financial - 472K
Two Sigma - 263K
Royce Opportunity - 242K
PSABX - 226K
Bourne Lent - 211K
* * $RMED Video Chart 09-30-2020 * *
Link to Video - click here to watch the technical chart video
$RMED Based on 2 analysts offering 12 month price targets for Ra Medical Systems in the last 3 months. The average price target is $0.75 with a high forecast of $1.00
Ra Medical Systems, Inc.
Shares Outstanding
72,468,300
Float
64,601,069
Insider Ownership
0.80%
Insitutional Ownership
7.80%
WAAAAYY over sold.
Zacks upgrades to a buy.
Funds bought 30% of the outstanding float last QTR.
Short squeeze coming.
Trades at $17M Market cap, They have $42M cash on hand.
Best Earnings report in 5 years.
$RMED WAAAAYY over sold.
— This and That (@ScotchStocks) August 22, 2020
Zacks upgrades to a buy.
Funds bought 30% of the outstanding float last QTR.
Short squeeze coming.
Trades at $17M Market cap, They have $42M cash on hand.
Best Earnings report in 5 years.#10bagger #Markets #stocks #DDTG #fintwits
Has a $MARA run in it
Building momentum. Decent short interest last few days. Took starter after hours. Could get interesting.
Cash in hand value is $.79
They have $41M cash and a $16M market cap
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
521
|
Created
|
08/15/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |